| Year |
Citation |
Score |
| 2020 |
Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of Plazomicin Tested against Isolates Collected from U.S. Hospitals (2016-2017): Effect of Different Breakpoint Criteria on in the Susceptibility Rates among Aminoglycosides. Antimicrobial Agents and Chemotherapy. PMID 32094137 DOI: 10.1128/AAC.02418-19 |
0.352 |
|
| 2019 |
Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy. PMID 31010862 DOI: 10.1128/AAC.00355-19 |
0.349 |
|
| 2019 |
Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN. Geographic and Temporal Patterns of Antimicrobial Resistance in Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016. Open Forum Infectious Diseases. 6: S63-S68. PMID 30895216 DOI: 10.1093/ofid/ofy343 |
0.308 |
|
| 2019 |
Fuhrmeister AS, Jones RN. The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases. 6: S1-S4. PMID 30895209 DOI: 10.1093/ofid/ofy346 |
0.301 |
|
| 2019 |
Jones RN, Barrett MS. Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 1: 35-43. PMID 11866719 DOI: 10.1111/J.1469-0691.1995.TB00022.X |
0.342 |
|
| 2019 |
Sader HS, Jones RN, Winokur PL, Pfaller MA, Doern GV, Barrett T. Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 5: 478-487. PMID 11856291 DOI: 10.1111/J.1469-0691.1999.TB00177.X |
0.375 |
|
| 2017 |
Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. The Pediatric Infectious Disease Journal. 36: 486-491. PMID 28403050 DOI: 10.1097/INF.0000000000001477 |
0.338 |
|
| 2017 |
Jones RN, Flamm RK, Castanheira M, Sader HS, Smart JI, Mendes RE. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. Diagnostic Microbiology and Infectious Disease. PMID 28377166 DOI: 10.1016/j.diagmicrobio.2017.03.003 |
0.361 |
|
| 2017 |
Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Clinical Isolates of Gram-negative Bacteria Collected Worldwide (2015). Antimicrobial Agents and Chemotherapy. PMID 28242660 DOI: 10.1128/AAC.00072-17 |
0.35 |
|
| 2017 |
Sader HS, Castanheira M, Mendes RE, Flamm RK, Jones RN. Antimicrobial Activity of High-proportion Cefepime-tazobactam (WCK 4282) When Tested against a Large Worldwide Collection of Gram-negative Organisms (2014). Antimicrobial Agents and Chemotherapy. PMID 28137811 DOI: 10.1128/AAC.02409-16 |
0.338 |
|
| 2016 |
Sader HS, Castanheira M, Jones RN, Flamm RK. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). Diagnostic Microbiology and Infectious Disease. PMID 28069328 DOI: 10.1016/j.diagmicrobio.2016.11.019 |
0.37 |
|
| 2016 |
Pfaller MA, Mendes RE, Flamm RK, Jones RN, Sader HS. Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. Microbial Drug Resistance (Larchmont, N.Y.). PMID 27918694 DOI: 10.1089/mdr.2016.0258 |
0.367 |
|
| 2016 |
Duncan LR, Smart JI, Flamm RK, Sader HS, Jones RN, Mendes RE. Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). Diagnostic Microbiology and Infectious Disease. PMID 27608537 DOI: 10.1016/j.diagmicrobio.2016.08.005 |
0.316 |
|
| 2016 |
Duncan LR, Sader HS, Flamm RK, Jones RN, Mendes RE. Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014). Diagnostic Microbiology and Infectious Disease. PMID 27543378 DOI: 10.1016/j.diagmicrobio.2016.07.025 |
0.308 |
|
| 2016 |
Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN, Flamm RK. Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015. Antimicrobial Agents and Chemotherapy. PMID 27401568 DOI: 10.1128/AAC.01267-16 |
0.312 |
|
| 2016 |
Sader HS, Mendes RE, Jones RN, Flamm RK. Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). Diagnostic Microbiology and Infectious Disease. PMID 27394637 DOI: 10.1016/j.diagmicrobio.2016.06.017 |
0.308 |
|
| 2016 |
Pfaller MA, Flamm RK, Jones RN, Farrell DJ, Mendes RE. Activity of Tedizolid and Linezolid as Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe and Latin American Countries (2014). Antimicrobial Agents and Chemotherapy. PMID 27353270 DOI: 10.1128/AAC.00881-16 |
0.319 |
|
| 2016 |
Flamm RK, Rhomberg PR, Farrell DJ, Jones RN. In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. Diagnostic Microbiology and Infectious Disease. PMID 27352729 DOI: 10.1016/j.diagmicrobio.2016.06.012 |
0.31 |
|
| 2016 |
Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, Jones RN. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014). International Journal of Antimicrobial Agents. PMID 27291285 DOI: 10.1016/j.ijantimicag.2016.04.021 |
0.347 |
|
| 2016 |
Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS, Mendes RE. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). International Journal of Antimicrobial Agents. PMID 27211209 DOI: 10.1016/j.ijantimicag.2016.04.009 |
0.315 |
|
| 2016 |
Sader HS, Castanheira M, Flamm RK, Jones RN. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-negative Organisms Isolated from Urinary Tract Infections in United States Medical Centers (2012-2014). Antimicrobial Agents and Chemotherapy. PMID 27114273 DOI: 10.1128/AAC.00405-16 |
0.345 |
|
| 2016 |
Flamm RK, Castanheira M, Streit JM, Jones RN. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagnostic Microbiology and Infectious Disease. PMID 27112832 DOI: 10.1016/j.diagmicrobio.2016.03.019 |
0.314 |
|
| 2016 |
Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN, Bradley JS. Evolution of Ceftaroline-Resistant MRSA in a Child with Cystic Fibrosis following Repeated Antibiotic Exposure. The Pediatric Infectious Disease Journal. PMID 27093165 DOI: 10.1097/INF.0000000000001171 |
0.31 |
|
| 2016 |
Farrell DJ, Flamm RK, Sader HS, Jones RN. Results from the Solithromycin International Surveillance Program (2014). Antimicrobial Agents and Chemotherapy. PMID 27044551 DOI: 10.1128/AAC.00185-16 |
0.351 |
|
| 2016 |
Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Oritavancin activity tested against molecularly-characterized staphylococci and enterococci displaying elevated linezolid MIC results. Antimicrobial Agents and Chemotherapy. PMID 27001823 DOI: 10.1128/AAC.00281-16 |
0.328 |
|
| 2016 |
Jones RN, Schuchert JE, Mendes RE. Dalbavancin Activity when Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011-2014). Antimicrobial Agents and Chemotherapy. PMID 27001811 DOI: 10.1128/AAC.00116-16 |
0.371 |
|
| 2016 |
Sader HS, Farrell DJ, Flamm RK, Streit JM, Mendes RE, Jones RN. Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. Diagnostic Microbiology and Infectious Disease. PMID 26971182 DOI: 10.1016/j.diagmicrobio.2016.01.010 |
0.338 |
|
| 2016 |
Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR, Mendes RE. Results from Oritavancin Resistance Surveillance Programs (2011-2014): Clarification for Using Vancomycin as a Surrogate to Infer Oritavancin Susceptibility. Antimicrobial Agents and Chemotherapy. PMID 26926647 DOI: 10.1128/AAC.03029-15 |
0.318 |
|
| 2016 |
Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE, Jones RN. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014). Antimicrobial Agents and Chemotherapy. PMID 26833165 DOI: 10.1128/AAC.02803-15 |
0.312 |
|
| 2015 |
Sader HS, Farrell DJ, Flamm RK, Jones RN. Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). Journal of Global Antimicrobial Resistance. 3: 161-165. PMID 27873705 DOI: 10.1016/j.jgar.2015.04.003 |
0.343 |
|
| 2015 |
Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK, Jones RN. β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. Antimicrobial Agents and Chemotherapy. PMID 26666936 DOI: 10.1128/AAC.01173-15 |
0.307 |
|
| 2015 |
Mendes RE, Watters AA, Rhomberg PR, Farrell DJ, Jones RN. Performance of BD MAX™ StaphSR for screening of methicillin-resistant Staphylococcus aureus among a contemporary and diverse collection from 146 institutions located in nine USA Census Regions: Prevalence of mecA drop-out mutants. Journal of Clinical Microbiology. PMID 26537444 DOI: 10.1128/JCM.02047-15 |
0.332 |
|
| 2015 |
Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN, Flamm RK. Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole. Microbial Drug Resistance (Larchmont, N.Y.). PMID 26230870 DOI: 10.1089/mdr.2014.0307 |
0.321 |
|
| 2015 |
Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagnostic Microbiology and Infectious Disease. 83: 183-6. PMID 26164275 DOI: 10.1016/j.diagmicrobio.2015.06.011 |
0.359 |
|
| 2015 |
Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagnostic Microbiology and Infectious Disease. 83: 389-94. PMID 26162518 DOI: 10.1016/j.diagmicrobio.2015.06.008 |
0.307 |
|
| 2015 |
McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW. In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program. Antimicrobial Agents and Chemotherapy. 59: 5007-9. PMID 25987636 DOI: 10.1128/AAC.00274-15 |
0.34 |
|
| 2015 |
Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. International Journal of Antimicrobial Agents. 46: 53-9. PMID 25956844 DOI: 10.1016/j.ijantimicag.2015.02.022 |
0.317 |
|
| 2015 |
Pfaller MA, Messer SA, Jones RN, Castanheira M. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). The Journal of Antibiotics. PMID 25899126 DOI: 10.1038/ja.2015.29 |
0.341 |
|
| 2015 |
Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrobial Agents and Chemotherapy. 59: 3509-17. PMID 25845862 DOI: 10.1128/AAC.00163-15 |
0.322 |
|
| 2015 |
Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrobial Agents and Chemotherapy. 59: 3656-9. PMID 25845861 DOI: 10.1128/AAC.05024-14 |
0.339 |
|
| 2015 |
Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrobial Agents and Chemotherapy. 59: 3263-70. PMID 25801559 DOI: 10.1128/AAC.04839-14 |
0.378 |
|
| 2015 |
Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagnostic Microbiology and Infectious Disease. 82: 73-7. PMID 25724854 DOI: 10.1016/j.diagmicrobio.2015.01.017 |
0.329 |
|
| 2015 |
Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M, Jones RN. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagnostic Microbiology and Infectious Disease. 82: 78-84. PMID 25708896 DOI: 10.1016/j.diagmicrobio.2015.01.015 |
0.342 |
|
| 2015 |
Flamm RK, Rhomberg PR, Kaplan N, Jones RN, Farrell DJ. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrobial Agents and Chemotherapy. 59: 2583-7. PMID 25691627 DOI: 10.1128/AAC.05119-14 |
0.363 |
|
| 2015 |
Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Antimicrobial Agents and Chemotherapy. 59: 2405-9. PMID 25666152 DOI: 10.1128/AAC.05098-14 |
0.333 |
|
| 2015 |
Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrobial Agents and Chemotherapy. 59: 2458-61. PMID 25645844 DOI: 10.1128/AAC.04614-14 |
0.368 |
|
| 2015 |
Flamm RK, Rhomberg PR, Jones RN, Farrell DJ. In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 59: 2280-5. PMID 25645834 DOI: 10.1128/AAC.04840-14 |
0.343 |
|
| 2015 |
Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ, Jones RN. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagnostic Microbiology and Infectious Disease. 81: 283-9. PMID 25633420 DOI: 10.1016/j.diagmicrobio.2014.12.009 |
0.32 |
|
| 2015 |
Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagnostic Microbiology and Infectious Disease. 81: 275-9. PMID 25618421 DOI: 10.1016/j.diagmicrobio.2014.12.011 |
0.339 |
|
| 2015 |
Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS, Jones RN. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. Antimicrobial Agents and Chemotherapy. 59: 1751-4. PMID 25583717 DOI: 10.1128/AAC.04773-14 |
0.355 |
|
| 2015 |
Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrobial Agents and Chemotherapy. 59: 1811-4. PMID 25561335 DOI: 10.1128/AAC.04616-14 |
0.343 |
|
| 2015 |
Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method. Antimicrobial Agents and Chemotherapy. 59: 702-6. PMID 25348529 DOI: 10.1128/AAC.04052-14 |
0.342 |
|
| 2014 |
Flamm RK, Jones RN, Sader HS. In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). Journal of Global Antimicrobial Resistance. 2: 183-189. PMID 27873727 DOI: 10.1016/j.jgar.2014.02.006 |
0.306 |
|
| 2014 |
Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: S367-73. PMID 25371512 DOI: 10.1093/cid/ciu706 |
0.359 |
|
| 2014 |
Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012). The Pediatric Infectious Disease Journal. 33: 837-42. PMID 25222304 DOI: 10.1097/INF.0000000000000307 |
0.328 |
|
| 2014 |
Castanheira M, Messer SA, Jones RN, Farrell DJ, Pfaller MA. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections International Journal of Antimicrobial Agents. 44: 320-326. PMID 25129315 DOI: 10.1016/j.ijantimicag.2014.06.007 |
0.37 |
|
| 2014 |
Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagnostic Microbiology and Infectious Disease. 80: 233-8. PMID 25128477 DOI: 10.1016/j.diagmicrobio.2014.07.005 |
0.367 |
|
| 2014 |
Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia. 178: 1-9. PMID 24952015 DOI: 10.1007/s11046-014-9772-2 |
0.327 |
|
| 2014 |
Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). The Journal of Antimicrobial Chemotherapy. 69: 2713-22. PMID 24917579 DOI: 10.1093/jac/dku184 |
0.317 |
|
| 2014 |
Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 17: 1-12. PMID 24880801 DOI: 10.1016/j.drup.2014.04.002 |
0.366 |
|
| 2014 |
Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrobial Agents and Chemotherapy. 58: 4923-7. PMID 24867974 DOI: 10.1128/AAC.02976-14 |
0.341 |
|
| 2014 |
Farrell DJ, Flamm RK, Sader HS, Jones RN. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrobial Agents and Chemotherapy. 58: 3882-8. PMID 24777091 DOI: 10.1128/AAC.02465-14 |
0.379 |
|
| 2014 |
Sader HS, Farrell DJ, Flamm RK, Jones RN. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). International Journal of Antimicrobial Agents. 43: 465-9. PMID 24636430 DOI: 10.1016/j.ijantimicag.2014.01.018 |
0.323 |
|
| 2014 |
Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. International Journal of Antimicrobial Agents. 43: 328-34. PMID 24630306 DOI: 10.1016/j.ijantimicag.2014.01.007 |
0.339 |
|
| 2014 |
Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrobial Agents and Chemotherapy. 58: 2921-4. PMID 24550323 DOI: 10.1128/AAC.02482-13 |
0.315 |
|
| 2014 |
Flamm RK, Farrell DJ, Sader HS, Jones RN. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). Diagnostic Microbiology and Infectious Disease. 78: 449-56. PMID 24529941 DOI: 10.1016/j.diagmicrobio.2014.01.003 |
0.354 |
|
| 2014 |
Flamm RK, Sader HS, Farrell DJ, Jones RN. Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers. Antimicrobial Agents and Chemotherapy. 58: 2468-71. PMID 24514082 DOI: 10.1128/AAC.02557-13 |
0.364 |
|
| 2014 |
Flamm RK, Sader HS, Jones RN. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases. 18: 187-95. PMID 24513484 DOI: 10.1016/j.bjid.2013.11.005 |
0.333 |
|
| 2014 |
Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrobial Agents and Chemotherapy. 58: 2274-80. PMID 24492361 DOI: 10.1128/AAC.02684-13 |
0.382 |
|
| 2014 |
Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagnostic Microbiology and Infectious Disease. 78: 443-8. PMID 24492025 DOI: 10.1016/j.diagmicrobio.2013.11.025 |
0.33 |
|
| 2014 |
Pfaller MA, Flamm RK, Sader HS, Jones RN. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagnostic Microbiology and Infectious Disease. 78: 422-8. PMID 24445158 DOI: 10.1016/j.diagmicrobio.2013.08.027 |
0.374 |
|
| 2014 |
Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrobial Agents and Chemotherapy. 58: 1243-7. PMID 24323470 DOI: 10.1128/AAC.02112-13 |
0.319 |
|
| 2014 |
Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrobial Agents and Chemotherapy. 58: 833-8. PMID 24247134 DOI: 10.1128/AAC.01896-13 |
0.303 |
|
| 2013 |
Flamm RK, Sader HS, Jones RN. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagnostic Microbiology and Infectious Disease. 78: 437-42. PMID 24582578 DOI: 10.1016/j.diagmicrobio.2013.10.020 |
0.396 |
|
| 2013 |
Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. Resistance surveillance program report for selected European nations (2011). Diagnostic Microbiology and Infectious Disease. 78: 429-36. PMID 24440509 DOI: 10.1016/j.diagmicrobio.2013.10.008 |
0.335 |
|
| 2013 |
Farrell DJ, Flamm RK, Sader HS, Jones RN. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. International Journal of Antimicrobial Agents. 43: 323-7. PMID 24411474 DOI: 10.1016/j.ijantimicag.2013.11.005 |
0.324 |
|
| 2013 |
Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrobial Agents and Chemotherapy. 58: 1684-92. PMID 24379201 DOI: 10.1128/AAC.02429-13 |
0.338 |
|
| 2013 |
Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrobial Agents and Chemotherapy. 57: 6305-10. PMID 24100499 DOI: 10.1128/AAC.01802-13 |
0.374 |
|
| 2013 |
Castanheira M, Jones RN, Sader HS. Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. Journal of Chemotherapy (Florence, Italy). 26: 202-10. PMID 24070006 DOI: 10.1179/1973947813Y.0000000135 |
0.314 |
|
| 2013 |
Mendes RE, Mendoza M, Banga Singh KK, Castanheira M, Bell JM, Turnidge JD, Lin SS, Jones RN. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrobial Agents and Chemotherapy. 57: 5721-6. PMID 23959306 DOI: 10.1128/AAC.01121-13 |
0.351 |
|
| 2013 |
Flamm RK, Sader HS, Jones RN. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases. 17: 564-72. PMID 23916453 DOI: 10.1016/j.bjid.2013.02.008 |
0.336 |
|
| 2013 |
Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrobial Agents and Chemotherapy. 57: 4489-95. PMID 23836172 DOI: 10.1128/AAC.00358-13 |
0.369 |
|
| 2013 |
Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds Journal of Clinical Microbiology. 51: 2608-2616. PMID 23740727 DOI: 10.1128/JCM.00863-13 |
0.311 |
|
| 2013 |
Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance Journal of Clinical Microbiology. 51: 2571-2581. PMID 23720791 DOI: 10.1128/JCM.00308-13 |
0.367 |
|
| 2013 |
Mendes RE, Deshpande LM, Kim J, Myers DS, Ross JE, Jones RN. Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents. Journal of Clinical Microbiology. 51: 2728-31. PMID 23698536 DOI: 10.1128/JCM.00757-13 |
0.303 |
|
| 2013 |
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrobial Agents and Chemotherapy. 57: 3178-81. PMID 23629712 DOI: 10.1128/AAC.00484-13 |
0.367 |
|
| 2013 |
Picão RC, Jones RN, Mendes RE, Castanheira M. Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods. Journal of Clinical Microbiology. 51: 2388-90. PMID 23616458 DOI: 10.1128/JCM.00640-13 |
0.328 |
|
| 2013 |
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagnostic Microbiology and Infectious Disease. 76: 61-8. PMID 23535208 DOI: 10.1016/j.diagmicrobio.2013.01.005 |
0.379 |
|
| 2013 |
Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagnostic Microbiology and Infectious Disease. 76: 217-21. PMID 23522845 DOI: 10.1016/j.diagmicrobio.2013.02.009 |
0.383 |
|
| 2013 |
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagnostic Microbiology and Infectious Disease. 75: 417-22. PMID 23514757 DOI: 10.1016/j.diagmicrobio.2013.01.001 |
0.378 |
|
| 2013 |
Jones RN, Wilson ML, Weinstein MP, Stilwell MG, Mendes RE. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. Diagnostic Microbiology and Infectious Disease. 75: 402-5. PMID 23514756 DOI: 10.1016/j.diagmicrobio.2013.01.022 |
0.392 |
|
| 2013 |
Mendes RE, Alley MR, Sader HS, Biedenbach DJ, Jones RN. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 57: 2849-57. PMID 23507283 DOI: 10.1128/AAC.00160-13 |
0.309 |
|
| 2013 |
Jones RN, Stilwell MG, Wilson ML, Mendes RE. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease. 76: 69-72. PMID 23490012 DOI: 10.1016/j.diagmicrobio.2013.01.023 |
0.31 |
|
| 2013 |
Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagnostic Microbiology and Infectious Disease. 76: 206-13. PMID 23478031 DOI: 10.1016/j.diagmicrobio.2013.01.025 |
0.363 |
|
| 2013 |
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011. Antimicrobial Agents and Chemotherapy. 57: 1982-8. PMID 23380730 DOI: 10.1128/AAC.02436-12 |
0.341 |
|
| 2013 |
Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagnostic Microbiology and Infectious Disease. 75: 304-7. PMID 23357293 DOI: 10.1016/j.diagmicrobio.2012.11.024 |
0.337 |
|
| 2013 |
Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrobial Agents and Chemotherapy. 57: 1065-8. PMID 23229479 DOI: 10.1128/AAC.01588-12 |
0.3 |
|
| 2013 |
Jones RN, Flamm RK, Sader HS, Stilwell MG. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. Diagnostic Microbiology and Infectious Disease. 75: 89-93. PMID 23023107 DOI: 10.1016/j.diagmicrobio.2012.08.022 |
0.316 |
|
| 2012 |
Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. Journal of Chemotherapy (Florence, Italy). 24: 328-37. PMID 23174097 DOI: 10.1179/1973947812Y.0000000039 |
0.383 |
|
| 2012 |
Farrell DJ, Flamm RK, Jones RN, Sader HS. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagnostic Microbiology and Infectious Disease. 75: 86-8. PMID 23146404 DOI: 10.1016/j.diagmicrobio.2012.06.005 |
0.4 |
|
| 2012 |
Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagnostic Microbiology and Infectious Disease. 75: 107-9. PMID 23009730 DOI: 10.1016/j.diagmicrobio.2012.08.024 |
0.356 |
|
| 2012 |
Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S206-14. PMID 22903953 DOI: 10.1093/cid/cis563 |
0.396 |
|
| 2012 |
Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S194-205. PMID 22903952 DOI: 10.1093/cid/cis562 |
0.369 |
|
| 2012 |
Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S187-93. PMID 22903951 DOI: 10.1093/cid/cis561 |
0.37 |
|
| 2012 |
Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S181-6. PMID 22903950 DOI: 10.1093/cid/cis560 |
0.339 |
|
| 2012 |
Biedenbach DJ, Turner LL, Jones RN, Farrell DJ. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains Diagnostic Microbiology and Infectious Disease. 74: 204-206. PMID 22819604 DOI: 10.1016/j.diagmicrobio.2012.06.006 |
0.337 |
|
| 2012 |
Flamm RK, Sader HS, Farrell DJ, Jones RN. Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. Diagnostic Microbiology and Infectious Disease. 74: 198-200. PMID 22819241 DOI: 10.1016/j.diagmicrobio.2012.06.007 |
0.332 |
|
| 2012 |
Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrobial Agents and Chemotherapy. 56: 4779-85. PMID 22733066 DOI: 10.1128/AAC.00817-12 |
0.328 |
|
| 2012 |
Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagnostic Microbiology and Infectious Disease. 74: 54-61. PMID 22704791 DOI: 10.1016/j.diagmicrobio.2012.05.012 |
0.338 |
|
| 2012 |
Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagnostic Microbiology and Infectious Disease. 73: 354-60. PMID 22656912 DOI: 10.1016/j.diagmicrobio.2012.04.007 |
0.341 |
|
| 2012 |
Sader HS, Jones RN. Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. Diagnostic Microbiology and Infectious Disease. 73: 212-4. PMID 22608137 DOI: 10.1016/j.diagmicrobio.2012.02.005 |
0.341 |
|
| 2012 |
Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrobial Agents and Chemotherapy. 56: 3999-4004. PMID 22508304 DOI: 10.1128/AAC.00011-12 |
0.336 |
|
| 2012 |
Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrobial Agents and Chemotherapy. 56: 2933-40. PMID 22470115 DOI: 10.1128/AAC.00330-12 |
0.386 |
|
| 2012 |
Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S203-13. PMID 22431850 DOI: 10.1093/cid/cir923 |
0.353 |
|
| 2012 |
Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. The Journal of Antimicrobial Chemotherapy. 67: 1321-4. PMID 22398650 DOI: 10.1093/jac/dks069 |
0.316 |
|
| 2012 |
Castanheira M, Deshpande LM, Jones RN, Farrell DJ. Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones Diagnostic Microbiology and Infectious Disease. 72: 263-266. PMID 22321998 DOI: 10.1016/j.diagmicrobio.2011.12.001 |
0.309 |
|
| 2012 |
Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy. 56: 1619-23. PMID 22232289 DOI: 10.1128/AAC.05789-11 |
0.322 |
|
| 2011 |
Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrobial Agents and Chemotherapy. 56: 1639-42. PMID 22183169 DOI: 10.1128/AAC.06067-11 |
0.344 |
|
| 2011 |
Mendes RE, Sader HS, Farrell DJ, Jones RN. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009). Diagnostic Microbiology and Infectious Disease. 72: 113-7. PMID 22078909 DOI: 10.1016/j.diagmicrobio.2011.09.023 |
0.342 |
|
| 2011 |
Farrell DJ, Liverman LC, Biedenbach DJ, Flamm RK, Jones RN. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease. 71: 415-20. PMID 21982563 DOI: 10.1016/j.diagmicrobio.2011.08.011 |
0.334 |
|
| 2011 |
Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method Diagnostic Microbiology and Infectious Disease. 71: 252-259. PMID 21917395 DOI: 10.1016/j.diagmicrobio.2011.07.007 |
0.339 |
|
| 2011 |
Mendes RE, Sader HS, Farrell DJ, Jones RN. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagnostic Microbiology and Infectious Disease. 71: 93-7. PMID 21851873 DOI: 10.1016/j.diagmicrobio.2011.05.012 |
0.353 |
|
| 2011 |
Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrobial Agents and Chemotherapy. 55: 3684-90. PMID 21670176 DOI: 10.1128/AAC.01729-10 |
0.344 |
|
| 2011 |
Jones RN, Mendes RE, Sader HS, Castanheira M. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S477-86. PMID 21546624 DOI: 10.1093/cid/cir163 |
0.328 |
|
| 2011 |
Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagnostic Microbiology and Infectious Disease. 70: 412-6. PMID 21546202 DOI: 10.1016/j.diagmicrobio.2011.02.008 |
0.37 |
|
| 2011 |
Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009) International Journal of Antimicrobial Agents. 38: 65-69. PMID 21514797 DOI: 10.1016/j.ijantimicag.2011.02.016 |
0.333 |
|
| 2011 |
Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrobial Agents and Chemotherapy. 55: 2390-4. PMID 21321149 DOI: 10.1128/AAC.01737-10 |
0.34 |
|
| 2011 |
Sader HS, Farrell DJ, Jones RN. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009) Diagnostic Microbiology and Infectious Disease. 69: 223-227. PMID 21251571 DOI: 10.1016/j.diagmicrobio.2010.10.020 |
0.386 |
|
| 2011 |
Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009) Diagnostic Microbiology and Infectious Disease. 69: 45-50. PMID 21146713 DOI: 10.1016/j.diagmicrobio.2010.08.013 |
0.348 |
|
| 2011 |
Mendes RE, Farrell DJ, Sader HS, Jones RN. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagnostic Microbiology and Infectious Disease. 68: 307-11. PMID 20955916 DOI: 10.1016/j.diagmicrobio.2010.07.003 |
0.334 |
|
| 2010 |
Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program. Diagnostic Microbiology and Infectious Disease. 68: 459-67. PMID 21094428 DOI: 10.1016/j.diagmicrobio.2010.09.018 |
0.362 |
|
| 2010 |
Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagnostic Microbiology and Infectious Disease. 67: 359-68. PMID 20638605 DOI: 10.1016/j.diagmicrobio.2010.03.009 |
0.346 |
|
| 2010 |
Biedenbach DJ, Castanheira M, Jones RN. Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. Antimicrobial Agents and Chemotherapy. 54: 4009-11. PMID 20625152 DOI: 10.1128/AAC.01812-09 |
0.344 |
|
| 2010 |
Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). International Journal of Antimicrobial Agents. 36: 374-9. PMID 20598860 DOI: 10.1016/j.ijantimicag.2010.05.016 |
0.345 |
|
| 2010 |
Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrobial Agents and Chemotherapy. 54: 3614-7. PMID 20566766 DOI: 10.1128/AAC.01390-09 |
0.336 |
|
| 2010 |
Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagnostic Microbiology and Infectious Disease. 67: 266-9. PMID 20471765 DOI: 10.1016/j.diagmicrobio.2010.02.014 |
0.311 |
|
| 2010 |
Sader HS, Farrell DJ, Jones RN. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres International Journal of Antimicrobial Agents. 36: 28-32. PMID 20444576 DOI: 10.1016/j.ijantimicag.2010.03.016 |
0.348 |
|
| 2010 |
Mendes RE, Moet GJ, Janechek MJ, Jones RN. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrobial Agents and Chemotherapy. 54: 2704-6. PMID 20385851 DOI: 10.1128/AAC.00301-10 |
0.352 |
|
| 2010 |
Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections Antimicrobial Agents and Chemotherapy. 54: 2735-2737. PMID 20368399 DOI: 10.1128/AAC.01774-09 |
0.344 |
|
| 2010 |
Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy. 54: 2716-9. PMID 20308374 DOI: 10.1128/AAC.01797-09 |
0.328 |
|
| 2010 |
Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. International Journal of Antimicrobial Agents. 35: 537-43. PMID 20211548 DOI: 10.1016/j.ijantimicag.2010.01.026 |
0.328 |
|
| 2010 |
Woosley LN, Castanheira M, Jones RN. CEM-101 activity against Gram-positive organisms. Antimicrobial Agents and Chemotherapy. 54: 2182-7. PMID 20176910 DOI: 10.1128/AAC.01662-09 |
0.362 |
|
| 2010 |
Sader HS, Becker HK, Moet GJ, Jones RN. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008). Diagnostic Microbiology and Infectious Disease. 66: 329-31. PMID 20159377 DOI: 10.1016/j.diagmicrobio.2009.09.017 |
0.348 |
|
| 2010 |
Jones RN, Castanheira M, Rhomberg PR, Woosley LN, Pfaller MA. Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus. Journal of Clinical Microbiology. 48: 972-6. PMID 20053856 DOI: 10.1128/JCM.01829-09 |
0.305 |
|
| 2010 |
Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease. 66: 393-401. PMID 20022192 DOI: 10.1016/j.diagmicrobio.2009.10.013 |
0.322 |
|
| 2010 |
Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. Journal of Clinical Microbiology. 48: 568-74. PMID 19940054 DOI: 10.1128/Jcm.01384-09 |
0.346 |
|
| 2010 |
Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagnostic Microbiology and Infectious Disease. 65: 414-26. PMID 19833471 DOI: 10.1016/j.diagmicrobio.2009.08.020 |
0.366 |
|
| 2009 |
Pfaller MA, Castanheira M, Sader HS, Jones RN. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. International Journal of Antimicrobial Agents. 35: 282-7. PMID 20036520 DOI: 10.1016/j.ijantimicag.2009.10.023 |
0.335 |
|
| 2009 |
Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagnostic Microbiology and Infectious Disease. 65: 404-13. PMID 19913683 DOI: 10.1016/j.diagmicrobio.2009.10.001 |
0.382 |
|
| 2009 |
Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagnostic Microbiology and Infectious Disease. 65: 392-403. PMID 19913682 DOI: 10.1016/j.diagmicrobio.2009.10.011 |
0.336 |
|
| 2009 |
Mendes RE, Jones RN, Deshpande LM, Ross JE, Sader HS. Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates. Microbial Drug Resistance (Larchmont, N.Y.). 15: 245-9. PMID 19857129 DOI: 10.1089/mdr.2009.0045 |
0.358 |
|
| 2009 |
Jones RN, Stilwell MG, Rhomberg PR, Sader HS. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagnostic Microbiology and Infectious Disease. 65: 331-4. PMID 19822273 DOI: 10.1016/j.diagmicrobio.2009.06.022 |
0.317 |
|
| 2009 |
Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagnostic Microbiology and Infectious Disease. 65: 158-62. PMID 19748426 DOI: 10.1016/j.diagmicrobio.2009.06.016 |
0.374 |
|
| 2009 |
Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. The Journal of Antimicrobial Chemotherapy. 64: 1024-8. PMID 19744978 DOI: 10.1093/jac/dkp319 |
0.314 |
|
| 2009 |
Sader HS, Fey PD, Fish DN, Limaye AP, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006 Antimicrobial Agents and Chemotherapy. 53: 4127-4132. PMID 19635961 DOI: 10.1128/Aac.00616-09 |
0.32 |
|
| 2009 |
Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagnostic Microbiology and Infectious Disease. 64: 191-201. PMID 19500528 DOI: 10.1016/j.diagmicrobio.2009.03.001 |
0.377 |
|
| 2009 |
Bell JM, Turnidge JD, Jones RN. Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report. Journal of Clinical Microbiology. 47: 2187-93. PMID 19458179 DOI: 10.1128/JCM.00304-09 |
0.304 |
|
| 2009 |
Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 53: 3162-5. PMID 19398641 DOI: 10.1128/AAC.00093-09 |
0.329 |
|
| 2009 |
Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 53: 2360-6. PMID 19349512 DOI: 10.1128/AAC.01452-08 |
0.359 |
|
| 2009 |
Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagnostic Microbiology and Infectious Disease. 64: 202-12. PMID 19321284 DOI: 10.1016/j.diagmicrobio.2009.01.017 |
0.335 |
|
| 2009 |
Fritsche TR, Sader HS, Stillwell MG, Jones RN. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007). Diagnostic Microbiology and Infectious Disease. 63: 440-6. PMID 19302928 DOI: 10.1016/j.diagmicrobio.2009.01.019 |
0.358 |
|
| 2009 |
Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrobial Agents and Chemotherapy. 53: 2171-5. PMID 19289528 DOI: 10.1128/AAC.00129-09 |
0.364 |
|
| 2009 |
Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagnostic Microbiology and Infectious Disease. 63: 426-33. PMID 19249180 DOI: 10.1016/j.diagmicrobio.2009.01.026 |
0.369 |
|
| 2009 |
Biedenbach DJ, Jones RN. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagnostic Microbiology and Infectious Disease. 64: 177-84. PMID 19249179 DOI: 10.1016/j.diagmicrobio.2008.12.019 |
0.366 |
|
| 2009 |
Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrobial Agents and Chemotherapy. 53: 1260-3. PMID 19124664 DOI: 10.1128/AAC.01453-08 |
0.374 |
|
| 2009 |
Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN, Pfaller MA. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagnostic Microbiology and Infectious Disease. 63: 233-6. PMID 19070452 DOI: 10.1016/j.diagmicrobio.2008.11.001 |
0.328 |
|
| 2008 |
Loza E, Morosini MI, Pascual A, Tubau F, Alcalá J, Liñares J, Hernández-Bello JR, Baquero F, Perea E, Martín R, Jones RN, Cantón R. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)]. Enfermedades Infecciosas Y Microbiologia Clinica. 26: 489-94. PMID 19094861 |
0.324 |
|
| 2008 |
Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagnostic Microbiology and Infectious Disease. 62: 416-26. PMID 19022153 DOI: 10.1016/j.diagmicrobio.2008.10.010 |
0.338 |
|
| 2008 |
Mendes RE, Fritsche TR, Sader HS, Jones RN. Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 46: 1324-6. PMID 18444879 DOI: 10.1086/533476 |
0.32 |
|
| 2008 |
Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrobial Agents and Chemotherapy. 52: 2244-6. PMID 18391032 DOI: 10.1128/AAC.00231-08 |
0.314 |
|
| 2008 |
Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagnostic Microbiology and Infectious Disease. 61: 86-95. PMID 18385000 DOI: 10.1016/j.diagmicrobio.2008.02.008 |
0.366 |
|
| 2008 |
Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagnostic Microbiology and Infectious Disease. 61: 96-102. PMID 18384996 DOI: 10.1016/J.Diagmicrobio.2008.02.013 |
0.302 |
|
| 2008 |
Biedenbach DJ, Jones RN, Fritsche TR. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagnostic Microbiology and Infectious Disease. 61: 240-4. PMID 18353594 DOI: 10.1016/j.diagmicrobio.2008.01.015 |
0.329 |
|
| 2008 |
Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance Diagnostic Microbiology and Infectious Disease. 61: 203-213. PMID 18329835 DOI: 10.1016/j.diagmicrobio.2008.01.017 |
0.371 |
|
| 2008 |
Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). Diagnostic Microbiology and Infectious Disease. 61: 235-9. PMID 18314293 DOI: 10.1016/j.diagmicrobio.2008.01.016 |
0.367 |
|
| 2008 |
Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 52: 1153-5. PMID 18180353 DOI: 10.1128/AAC.01351-07 |
0.345 |
|
| 2008 |
Fritsche TR, Rhomberg PR, Sader HS, Jones RN. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease. 60: 399-403. PMID 18178361 DOI: 10.1016/j.diagmicrobio.2007.11.004 |
0.382 |
|
| 2008 |
Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. The Journal of Antimicrobial Chemotherapy. 61: 365-70. PMID 18079128 DOI: 10.1093/Jac/Dkm457 |
0.347 |
|
| 2008 |
Castanheira M, Sader HS, Jones RN, Debbia E, Picão RC, Gales AC. In71, an Enterobacter cloacae blaVIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: a SENTRY Antimicrobial Surveillance Program report. Microbial Drug Resistance (Larchmont, N.Y.). 13: 130-4. PMID 17650966 DOI: 10.1089/MDR.2007.728 |
0.338 |
|
| 2007 |
Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy. 52: 570-3. PMID 18070960 DOI: 10.1128/AAC.01114-07 |
0.347 |
|
| 2007 |
Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagnostic Microbiology and Infectious Disease. 60: 433-6. PMID 18068326 DOI: 10.1016/J.DIAGMICROBIO.2007.10.016 |
0.302 |
|
| 2007 |
Jones RN, Fritsche TR, Sader HS, Ross JE. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagnostic Microbiology and Infectious Disease. 59: 199-209. PMID 17908617 DOI: 10.1016/j.diagmicrobio.2007.06.001 |
0.39 |
|
| 2007 |
Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagnostic Microbiology and Infectious Disease. 59: 309-17. PMID 17720350 DOI: 10.1016/j.diagmicrobio.2007.06.004 |
0.364 |
|
| 2007 |
Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006) Diagnostic Microbiology and Infectious Disease. 59: 425-432. PMID 17662557 DOI: 10.1016/j.diagmicrobio.2007.05.009 |
0.363 |
|
| 2007 |
Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). International Journal of Antimicrobial Agents. 30: 143-9. PMID 17531446 DOI: 10.1016/J.IJANTIMICAG.2007.03.015 |
0.393 |
|
| 2007 |
Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR. Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. Antimicrobial Agents and Chemotherapy. 51: 2611-4. PMID 17470660 DOI: 10.1128/AAC.00838-06 |
0.312 |
|
| 2007 |
Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). Bmc Infectious Diseases. 7: 29. PMID 17442104 DOI: 10.1186/1471-2334-7-29 |
0.326 |
|
| 2007 |
Jones RN, Sader HS, Stilwell MG, Fritsche TR. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 58: 1-7. PMID 17408904 DOI: 10.1016/j.diagmicrobio.2007.01.019 |
0.369 |
|
| 2007 |
Jones RN, Fritsche TR, Sader HS, Stilwell MG. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagnostic Microbiology and Infectious Disease. 58: 9-17. PMID 17408903 DOI: 10.1016/j.diagmicrobio.2007.01.020 |
0.326 |
|
| 2007 |
Sader HS, Fritsche TR, Jones RN. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). Diagnostic Microbiology and Infectious Disease. 58: 27-32. PMID 17383140 DOI: 10.1016/J.DIAGMICROBIO.2006.12.006 |
0.386 |
|
| 2007 |
Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagnostic Microbiology and Infectious Disease. 58: 19-26. PMID 17383139 DOI: 10.1016/J.DIAGMICROBIO.2006.12.009 |
0.346 |
|
| 2007 |
Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease. 58: 163-70. PMID 17368801 DOI: 10.1016/J.DIAGMICROBIO.2006.12.022 |
0.327 |
|
| 2007 |
Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. International Journal of Antimicrobial Agents. 29: 295-301. PMID 17239570 DOI: 10.1016/j.ijantimicag.2006.09.025 |
0.352 |
|
| 2007 |
Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microbial Drug Resistance (Larchmont, N.Y.). 12: 223-30. PMID 17227206 DOI: 10.1089/MDR.2006.12.223 |
0.304 |
|
| 2007 |
Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. Journal of Clinical Microbiology. 45: 998-1004. PMID 17215346 DOI: 10.1128/JCM.02368-06 |
0.353 |
|
| 2007 |
Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy. 51: 1491-3. PMID 17210770 DOI: 10.1128/AAC.01496-06 |
0.336 |
|
| 2007 |
Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and Infectious Disease. 57: 7-13. PMID 17059876 DOI: 10.1016/j.diagmicrobio.2006.05.009 |
0.367 |
|
| 2006 |
Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari AC, Gales AC. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? MemóRias Do Instituto Oswaldo Cruz. 101: 741-8. PMID 17160281 DOI: 10.1590/S0074-02762006000700006 |
0.338 |
|
| 2006 |
Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagnostic Microbiology and Infectious Disease. 57: 341-4. PMID 17141461 DOI: 10.1016/J.DIAGMICROBIO.2006.08.016 |
0.323 |
|
| 2006 |
Pottumarthy S, Sader HS, Jones RN. Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 57: 345-9. PMID 17141459 DOI: 10.1016/J.DIAGMICROBIO.2006.08.022 |
0.308 |
|
| 2006 |
Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). International Journal of Antimicrobial Agents. 28: 578-81. PMID 17112706 DOI: 10.1016/J.IJANTIMICAG.2006.07.025 |
0.329 |
|
| 2006 |
Deshpande LM, Sader HS, Fritsche TR, Jones RN. Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). Journal of Clinical Microbiology. 44: 3775-7. PMID 17021108 DOI: 10.1128/JCM.00456-06 |
0.316 |
|
| 2006 |
Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagnostic Microbiology and Infectious Disease. 57: 333-6. PMID 16989974 DOI: 10.1016/J.DIAGMICROBIO.2006.08.001 |
0.342 |
|
| 2006 |
Jevitt LA, Thorne GM, Traczewski MM, Jones RN, McGowan JE, Tenover FC, Brown SD. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. Journal of Clinical Microbiology. 44: 3098-104. PMID 16954233 DOI: 10.1128/Jcm.00665-06 |
0.328 |
|
| 2006 |
Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagnostic Microbiology and Infectious Disease. 57: 207-15. PMID 16949243 DOI: 10.1016/J.DIAGMICROBIO.2006.07.009 |
0.383 |
|
| 2006 |
Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagnostic Microbiology and Infectious Disease. 56: 427-36. PMID 16938419 DOI: 10.1016/J.DIAGMICROBIO.2006.07.003 |
0.358 |
|
| 2006 |
Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and Infectious Disease. 57: 109-16. PMID 16930923 DOI: 10.1016/J.DIAGMICROBIO.2006.06.011 |
0.348 |
|
| 2006 |
Castanheira M, Gales AC, Pignatari AC, Jones RN, Sader HS. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Microbial Drug Resistance (Larchmont, N.Y.). 12: 91-8. PMID 16922623 DOI: 10.1089/MDR.2006.12.91 |
0.354 |
|
| 2006 |
Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America) Diagnostic Microbiology and Infectious Disease. 56: 75-82. PMID 16876375 DOI: 10.1016/j.diagmicrobio.2006.06.004 |
0.336 |
|
| 2006 |
Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrobial Agents and Chemotherapy. 50: 2583-6. PMID 16801451 DOI: 10.1128/AAC.01432-05 |
0.305 |
|
| 2006 |
Jones RN, Sader HS. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly? Diagnostic Microbiology and Infectious Disease. 55: 351-6. PMID 16765555 DOI: 10.1016/J.DIAGMICROBIO.2006.04.015 |
0.318 |
|
| 2006 |
Johnson DM, Fritsche TR, Sader HS, Jones RN. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. International Journal of Antimicrobial Agents. 27: 557-60. PMID 16698238 DOI: 10.1016/j.ijantimicag.2005.12.015 |
0.341 |
|
| 2006 |
Pfaller MA, Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and Infectious Disease. 56: 63-8. PMID 16650951 DOI: 10.1016/j.diagmicrobio.2006.02.009 |
0.355 |
|
| 2006 |
Streit JM, Jones RN, Toleman MA, Stratchounski LS, Fritsche TR. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003). International Journal of Antimicrobial Agents. 27: 367-75. PMID 16647842 DOI: 10.1016/j.ijantimicag.2005.12.004 |
0.376 |
|
| 2006 |
Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagnostic Microbiology and Infectious Disease. 56: 57-62. PMID 16631338 DOI: 10.1016/J.DIAGMICROBIO.2005.12.009 |
0.379 |
|
| 2006 |
Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagnostic Microbiology and Infectious Disease. 55: 119-27. PMID 16530373 DOI: 10.1016/J.DIAGMICROBIO.2005.12.006 |
0.339 |
|
| 2006 |
Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagnostic Microbiology and Infectious Disease. 54: 249-57. PMID 16466890 DOI: 10.1016/J.DIAGMICROBIO.2005.10.010 |
0.38 |
|
| 2006 |
Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagnostic Microbiology and Infectious Disease. 54: 83-7. PMID 16458124 DOI: 10.1016/J.DIAGMICROBIO.2005.09.004 |
0.316 |
|
| 2006 |
Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagnostic Microbiology and Infectious Disease. 54: 149-53. PMID 16426793 DOI: 10.1016/j.diagmicrobio.2005.08.015 |
0.356 |
|
| 2006 |
Deshpande LM, Sader HS, Debbia E, Nicoletti G, Fadda G, Jones RN. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Diagnostic Microbiology and Infectious Disease. 54: 157-64. PMID 16423493 DOI: 10.1016/J.DIAGMICROBIO.2005.08.012 |
0.342 |
|
| 2006 |
Pottumarthy S, Fritsche TR, Jones RN. Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes. Diagnostic Microbiology and Infectious Disease. 54: 127-34. PMID 16423492 DOI: 10.1016/J.DIAGMICROBIO.2005.08.013 |
0.35 |
|
| 2006 |
Jones RN, Li Q, Kohut B, Biedenbach DJ, Bell J, Turnidge JD. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagnostic Microbiology and Infectious Disease. 54: 63-71. PMID 16368476 DOI: 10.1016/j.diagmicrobio.2005.08.009 |
0.365 |
|
| 2006 |
Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S13-24. PMID 16323115 DOI: 10.1086/491710 |
0.357 |
|
| 2006 |
Fritsche TR, Jones RN. Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus. Journal of Drugs in Dermatology : Jdd. 4: s4-8. PMID 16300223 |
0.307 |
|
| 2006 |
Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagnostic Microbiology and Infectious Disease. 52: 265-73. PMID 16105569 DOI: 10.1016/J.DIAGMICROBIO.2005.02.003 |
0.394 |
|
| 2006 |
Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagnostic Microbiology and Infectious Disease. 52: 209-13. PMID 16105566 DOI: 10.1016/J.DIAGMICROBIO.2005.06.010 |
0.381 |
|
| 2006 |
Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagnostic Microbiology and Infectious Disease. 52: 203-8. PMID 16105565 DOI: 10.1016/J.DIAGMICROBIO.2005.05.002 |
0.391 |
|
| 2005 |
Gales AC, Jones RN, Andrade SS, Sader HS. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Memorias Do Instituto Oswaldo Cruz. 100: 571-7. PMID 16302068 DOI: 10.1590/S0074-02762005000600011 |
0.316 |
|
| 2005 |
Biedenbach DJ, Toleman M, Walsh TR, Jones RN. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagnostic Microbiology and Infectious Disease. 54: 13-21. PMID 16290025 DOI: 10.1016/J.DIAGMICROBIO.2005.06.013 |
0.363 |
|
| 2005 |
Jones RN, Critchley IA, Whittington WL, Janjic N, Pottumarthy S. Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. Diagnostic Microbiology and Infectious Disease. 53: 311-7. PMID 16269221 DOI: 10.1016/J.DIAGMICROBIO.2005.06.014 |
0.367 |
|
| 2005 |
Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagnostic Microbiology and Infectious Disease. 53: 329-32. PMID 16263233 DOI: 10.1016/J.DIAGMICROBIO.2005.07.001 |
0.371 |
|
| 2005 |
Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagnostic Microbiology and Infectious Disease. 52: 195-201. PMID 16105564 DOI: 10.1016/j.diagmicrobio.2005.05.003 |
0.356 |
|
| 2005 |
Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagnostic Microbiology and Infectious Disease. 52: 187-93. PMID 16105563 DOI: 10.1016/j.diagmicrobio.2005.05.004 |
0.361 |
|
| 2005 |
Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagnostic Microbiology and Infectious Disease. 52: 181-6. PMID 16105562 DOI: 10.1016/j.diagmicrobio.2005.05.005 |
0.376 |
|
| 2005 |
Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Seminars in Respiratory and Critical Care Medicine. 24: 121-34. PMID 16088531 DOI: 10.1055/S-2003-37923 |
0.331 |
|
| 2005 |
Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. International Journal of Antimicrobial Agents. 26: 13-21. PMID 15967640 DOI: 10.1016/j.ijantimicag.2005.02.019 |
0.373 |
|
| 2005 |
Jones RN, Fritsche TR, Sader HS. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 52: 129-33. PMID 15964501 DOI: 10.1016/J.DIAGMICROBIO.2004.12.009 |
0.366 |
|
| 2005 |
Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease. 53: 307-10. PMID 15922534 DOI: 10.1016/j.diagmicrobio.2005.03.004 |
0.382 |
|
| 2005 |
Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagnostic Microbiology and Infectious Disease. 52: 53-8. PMID 15878443 DOI: 10.1016/j.diagmicrobio.2004.12.013 |
0.38 |
|
| 2005 |
Sader HS, Jones RN. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. International Journal of Antimicrobial Agents. 25: 380-4. PMID 15848291 DOI: 10.1016/J.IJANTIMICAG.2005.01.011 |
0.327 |
|
| 2005 |
Fritsche TR, Sader HS, Cleeland R, Jones RN. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrobial Agents and Chemotherapy. 49: 1468-76. PMID 15793128 DOI: 10.1128/AAC.49.4.1468-1476.2005 |
0.322 |
|
| 2005 |
Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. International Journal of Antimicrobial Agents. 25: 282-9. PMID 15784306 DOI: 10.1016/j.ijantimicag.2004.12.001 |
0.36 |
|
| 2005 |
Pottumarthy S, Fritsche TR, Jones RN. Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagnostic Microbiology and Infectious Disease. 51: 147-50. PMID 15698723 DOI: 10.1016/J.DIAGMICROBIO.2004.09.007 |
0.347 |
|
| 2005 |
Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. International Journal of Antimicrobial Agents. 25: 95-109. PMID 15664479 DOI: 10.1016/J.IJANTIMICAG.2004.10.002 |
0.359 |
|
| 2005 |
Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN. Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. International Journal of Antimicrobial Agents. 25: 57-61. PMID 15620827 DOI: 10.1016/J.IJANTIMICAG.2004.08.013 |
0.358 |
|
| 2005 |
Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. International Journal of Antimicrobial Agents. 24: 567-71. PMID 15555879 DOI: 10.1016/J.IJANTIMICAG.2004.07.007 |
0.346 |
|
| 2004 |
Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagnostic Microbiology and Infectious Disease. 50: 201-4. PMID 15541606 DOI: 10.1016/j.diagmicrobio.2004.07.002 |
0.385 |
|
| 2004 |
Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagnostic Microbiology and Infectious Disease. 50: 73-5. PMID 15380281 DOI: 10.1016/J.DIAGMICROBIO.2004.04.011 |
0.363 |
|
| 2004 |
Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagnostic Microbiology and Infectious Disease. 50: 59-69. PMID 15380279 DOI: 10.1016/J.DIAGMICROBIO.2004.05.003 |
0.35 |
|
| 2004 |
Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. 8: 284-91. PMID 15325597 DOI: 10.1016/J.IJID.2003.11.009 |
0.318 |
|
| 2004 |
Rhomberg PR, Jones RN, Sader HS, Fritsche TR. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagnostic Microbiology and Infectious Disease. 49: 273-81. PMID 15313533 DOI: 10.1016/J.DIAGMICROBIO.2004.02.003 |
0.361 |
|
| 2004 |
Deshpande LM, Fritsche TR, Jones RN. Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease. 49: 231-6. PMID 15313526 DOI: 10.1016/J.DIAGMICROBIO.2004.03.014 |
0.336 |
|
| 2004 |
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). International Journal of Antimicrobial Agents. 24: 111-8. PMID 15288308 DOI: 10.1016/j.ijantimicag.2003.12.019 |
0.379 |
|
| 2004 |
Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001. The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases. 8: 25-79. PMID 15286878 DOI: 10.1590/S1413-86702004000100004 |
0.343 |
|
| 2004 |
Jones RN, Deshpande L, Fritsche TR, Sader HS. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). Diagnostic Microbiology and Infectious Disease. 49: 211-6. PMID 15246512 DOI: 10.1016/J.DIAGMICROBIO.2004.03.016 |
0.334 |
|
| 2004 |
Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections Diagnostic Microbiology and Infectious Disease. 49: 201-209. PMID 15246511 DOI: 10.1016/j.diagmicrobio.2004.03.002 |
0.339 |
|
| 2004 |
Jones RN, Fritsche TR, Sader HS. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagnostic Microbiology and Infectious Disease. 49: 63-5. PMID 15135503 DOI: 10.1016/J.DIAGMICROBIO.2003.12.005 |
0.325 |
|
| 2004 |
Yu WL, Chuang YC, Jones RN. A pragmatic approach to identify extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. Diagnostic Microbiology and Infectious Disease. 48: 277-82. PMID 15062921 DOI: 10.1016/J.DIAGMICROBIO.2003.11.001 |
0.362 |
|
| 2004 |
Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. The Journal of Antimicrobial Chemotherapy. 53: 669-74. PMID 14985278 DOI: 10.1093/jac/dkh143 |
0.308 |
|
| 2004 |
Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagnostic Microbiology and Infectious Disease. 48: 137-43. PMID 14972384 DOI: 10.1016/j.diagmicrobio.2003.09.004 |
0.38 |
|
| 2004 |
Rhomberg PR, Jones RN, Sader HS. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. International Journal of Antimicrobial Agents. 23: 52-9. PMID 14732314 DOI: 10.1016/J.IJANTIMICAG.2003.05.010 |
0.333 |
|
| 2004 |
Anderegg TR, Jones RN. Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. International Journal of Antimicrobial Agents. 23: 6-10. PMID 14732307 DOI: 10.1016/J.IJANTIMICAG.2003.05.007 |
0.357 |
|
| 2004 |
Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001) Journal of Clinical Microbiology. 42: 445-448. PMID 14715802 DOI: 10.1128/JCM.42.1.445-448.2004 |
0.347 |
|
| 2004 |
Sader HS, Johnson DM, Jones RN. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci. Antimicrobial Agents and Chemotherapy. 48: 53-62. PMID 14693518 DOI: 10.1128/AAC.48.1.53-62.2004 |
0.338 |
|
| 2004 |
Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). International Journal of Antimicrobial Agents. 22: 551-6. PMID 14659650 DOI: 10.1016/S0924-8579(03)00245-0 |
0.38 |
|
| 2004 |
Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagnostic Microbiology and Infectious Disease. 47: 515-25. PMID 14596971 DOI: 10.1016/S0732-8893(03)00165-2 |
0.314 |
|
| 2004 |
Mendes RE, Reis AO, Gales AC, Jones RN, Sader HS. Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000). The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases. 7: 282-9. PMID 14552736 DOI: 10.1590/S1413-86702003000500001 |
0.338 |
|
| 2004 |
Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagnostic Microbiology and Infectious Disease. 47: 435-40. PMID 14522519 DOI: 10.1016/S0732-8893(03)00114-7 |
0.303 |
|
| 2003 |
Gordon KA, Sader HS, Jones RN. Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States. Diagnostic Microbiology and Infectious Disease. 47: 377-83. PMID 12967754 DOI: 10.1016/S0732-8893(03)00096-8 |
0.386 |
|
| 2003 |
Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagnostic Microbiology and Infectious Disease. 47: 365-72. PMID 12967752 DOI: 10.1016/S0732-8893(03)00112-3 |
0.36 |
|
| 2003 |
Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease. 46: 285-9. PMID 12944021 DOI: 10.1016/S0732-8893(03)00087-7 |
0.338 |
|
| 2003 |
Deshpande LM, Jones RN. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: does it exist? Diagnostic Microbiology and Infectious Disease. 46: 223-5. PMID 12867099 DOI: 10.1016/S0732-8893(03)00050-6 |
0.338 |
|
| 2003 |
Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. The Annals of Pharmacotherapy. 37: 769-74. PMID 12773059 DOI: 10.1345/aph.1C437 |
0.317 |
|
| 2003 |
Jones RN, Biedenbach DJ, Beach ML. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease. 46: 77-80. PMID 12742324 DOI: 10.1016/S0732-8893(03)00015-4 |
0.301 |
|
| 2003 |
Mutnick AH, Biedenbach DJ, Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagnostic Microbiology and Infectious Disease. 46: 63-8. PMID 12742321 DOI: 10.1016/S0732-8893(03)00012-9 |
0.309 |
|
| 2003 |
Biedenbach DJ, Jones RN. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease. 46: 55-61. PMID 12742320 DOI: 10.1016/S0732-8893(03)00016-6 |
0.343 |
|
| 2003 |
Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagnostic Microbiology and Infectious Disease. 45: 295-301. PMID 12730002 DOI: 10.1016/S0732-8893(02)00467-4 |
0.345 |
|
| 2003 |
Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagnostic Microbiology and Infectious Disease. 45: 287-93. PMID 12730001 DOI: 10.1016/S0732-8893(02)00543-6 |
0.361 |
|
| 2003 |
Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagnostic Microbiology and Infectious Disease. 45: 279-85. PMID 12730000 DOI: 10.1016/S0732-8893(02)00540-0 |
0.356 |
|
| 2003 |
Jones RN, Biedenbach DJ. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). Diagnostic Microbiology and Infectious Disease. 45: 273-8. PMID 12729999 DOI: 10.1016/S0732-8893(03)00002-6 |
0.385 |
|
| 2003 |
Jones RN, Varnam DJ. Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Diagnostic Microbiology and Infectious Disease. 44: 379-82. PMID 12543544 DOI: 10.1016/S0732-8893(02)00442-X |
0.345 |
|
| 2003 |
Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). International Journal of Antimicrobial Agents. 21: 1-7. PMID 12507831 DOI: 10.1016/S0924-8579(02)00249-2 |
0.36 |
|
| 2003 |
Mutnick AH, Kirby JT, Jones RN. CANCER resistance surveillance program: Initial results from hematology-oncology centers in North America Annals of Pharmacotherapy. 37: 47-56. PMID 12503932 DOI: 10.1345/aph.1C292 |
0.367 |
|
| 2003 |
Jones RN, Rhomberg PR. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. The Journal of Antimicrobial Chemotherapy. 51: 157-61. PMID 12493802 DOI: 10.1093/JAC/DKG055 |
0.325 |
|
| 2003 |
Gales AC, Sader HS, Mendes RE, Jones RN. Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagnostic Microbiology and Infectious Disease. 44: 313-8. PMID 12493179 DOI: 10.1016/S0732-8893(02)00506-0 |
0.391 |
|
| 2003 |
Gales AC, Sader H HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagnostic Microbiology and Infectious Disease. 44: 301-11. PMID 12493178 DOI: 10.1016/S0732-8893(02)00499-6 |
0.387 |
|
| 2003 |
Gales AC, Sader HS, Jones RN. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagnostic Microbiology and Infectious Disease. 44: 289-99. PMID 12493177 DOI: 10.1016/S0732-8893(02)00470-4 |
0.372 |
|
| 2003 |
Sader HS, Jones RN, Silva JB. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagnostic Microbiology and Infectious Disease. 44: 281-8. PMID 12493176 DOI: 10.1016/S0732-8893(02)00468-6 |
0.368 |
|
| 2003 |
Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagnostic Microbiology and Infectious Disease. 44: 273-80. PMID 12493175 DOI: 10.1016/S0732-8893(02)00469-8 |
0.365 |
|
| 2003 |
Jones RN. Microbiology of newer fluoroquinolones: focus on respiratory pathogens. Diagnostic Microbiology and Infectious Disease. 44: 213-20. PMID 12493166 DOI: 10.1016/S0732-8893(02)00436-4 |
0.339 |
|
| 2003 |
Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. The Journal of Antimicrobial Chemotherapy. 50: 915-32. PMID 12461013 DOI: 10.1093/JAC/DKF249 |
0.376 |
|
| 2003 |
Jones RN, Rhomberg PR, Varnam DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India. International Journal of Antimicrobial Agents. 20: 426-31. PMID 12458136 DOI: 10.1016/S0924-8579(02)00210-8 |
0.342 |
|
| 2003 |
Ballow CH, Biedenbach DJ, Rossi F, Jones RN. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS). The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases. 6: 100-9. PMID 12144745 DOI: 10.1590/S1413-86702002000300001 |
0.386 |
|
| 2003 |
Turnidge J, Bell J, Biedenbach DJ, Jones RN. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999. International Journal of Antimicrobial Agents. 20: 10-7. PMID 12127706 DOI: 10.1016/S0924-8579(02)00050-X |
0.388 |
|
| 2003 |
Anderegg TR, Biedenbach DJ, Jones RN. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrobial Agents and Chemotherapy. 46: 2662-4. PMID 12121951 DOI: 10.1128/AAC.46.8.2662-2664.2002 |
0.363 |
|
| 2002 |
Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN, Kapil A, Chitnis DS, Lalitha MK, Arora A, Metha A, Sardana R, Venkatachalam N, Krishna Prakash S, Ayyagiri A, Kelkar R. Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against recent clinical isolates from India: A survey of ten medical center laboratories Diagnostic Microbiology and Infectious Disease. 44: 367-377. PMID 12543543 DOI: 10.1016/S0732-8893(02)00466-2 |
0.364 |
|
| 2002 |
Bell JM, Turnidge JD, Pfaller MA, Jones RN. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999). Diagnostic Microbiology and Infectious Disease. 43: 315-8. PMID 12151193 DOI: 10.1016/S0732-8893(02)00404-2 |
0.343 |
|
| 2002 |
Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (2000) Diagnostic Microbiology and Infectious Disease. 43: 303-309. PMID 12151191 DOI: 10.1016/S0732-8893(02)00415-7 |
0.379 |
|
| 2002 |
Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: Summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000) Diagnostic Microbiology and Infectious Disease. 43: 239-243. PMID 12106958 DOI: 10.1016/S0732-8893(02)00390-5 |
0.359 |
|
| 2002 |
Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagnostic Microbiology and Infectious Disease. 43: 157-62. PMID 12088624 DOI: 10.1016/S0732-8893(02)00374-7 |
0.31 |
|
| 2002 |
Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagnostic Microbiology and Infectious Disease. 43: 75-83. PMID 12052632 DOI: 10.1016/S0732-8893(01)00334-0 |
0.377 |
|
| 2002 |
Pfaller MA, Jones RN. Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. International Journal of Antimicrobial Agents. 19: 383-8. PMID 12007846 DOI: 10.1016/S0924-8579(02)00009-2 |
0.346 |
|
| 2002 |
Gordon KA, Pfaller MA, Jones RN. BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). The Journal of Antimicrobial Chemotherapy. 49: 851-5. PMID 12003983 |
0.301 |
|
| 2002 |
Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagnostic Microbiology and Infectious Disease. 42: 193-8. PMID 11929691 DOI: 10.1016/S0732-8893(01)00353-4 |
0.333 |
|
| 2002 |
Cereda RF, Gales AC, Silbert S, Jones RN, Sader HS. Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. Infection Control and Hospital Epidemiology. 23: 19-22. PMID 11868887 DOI: 10.1086/501962 |
0.302 |
|
| 2002 |
Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease. 42: 137-9. PMID 11858910 DOI: 10.1016/S0732-8893(01)00333-9 |
0.332 |
|
| 2002 |
Jones RN, Pfaller MA, Rhomberg PR, Walter DH. Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods. Journal of Clinical Microbiology. 40: 461-5. PMID 11825957 DOI: 10.1128/JCM.40.2.461-465.2002 |
0.31 |
|
| 1999 |
Jones RN, Croco MA, Pfaller MA, Beach ML, Kugler KC. Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 5: 540-546. PMID 11851706 DOI: 10.1111/J.1469-0691.1999.Tb00432.X |
0.36 |
|
| 1998 |
Fogt N, Jones R. The effect of forced vergence on retinal correspondence. Vision Research. 38: 2711-9. PMID 9775320 DOI: 10.1016/s0042-6989(97)00448-3 |
0.228 |
|
| 1998 |
Fogt N, Jones R. Comparison of fixation disparities obtained by objective and subjective methods. Vision Research. 38: 411-21. PMID 9536364 DOI: 10.1016/s0042-6989(97)00142-9 |
0.23 |
|
| 1997 |
Fogt N, Jones R. Comparison of the monocular occlusion and a direct method for objective measurement of fixation disparity. Optometry and Vision Science : Official Publication of the American Academy of Optometry. 74: 43-50. PMID 9148266 DOI: 10.1097/00006324-199701000-00019 |
0.222 |
|
| 1996 |
Fogt N, Jones R. The effect of refractive lenses on perceived direction. Vision Research. 36: 3735-41. PMID 8977003 DOI: 10.1016/0042-6989(96)00067-3 |
0.221 |
|
| 1990 |
Jones R. Do women and myopes have larger pupils? Investigative Ophthalmology & Visual Science. 31: 1413-5. PMID 2365574 |
0.205 |
|
| 1990 |
Polak NA, Jones R. Dynamic interactions between accommodation and convergence. Ieee Transactions On Bio-Medical Engineering. 37: 1011-4. PMID 2249859 DOI: 10.1109/10.102814 |
0.207 |
|
| 1990 |
Jones R. Physiological pseudomyopia. Optometry and Vision Science : Official Publication of the American Academy of Optometry. 67: 610-6. PMID 2216328 DOI: 10.1097/00006324-199008000-00010 |
0.224 |
|
| 1989 |
Jones R, Stephens GL. Horizontal fusional amplitudes: Evidence for disparity tuning Investigative Ophthalmology and Visual Science. 30: 1638-1642. PMID 2745003 |
0.225 |
|
| Show low-probability matches. |
